Skip to main content
. 2020 Aug 20;11:4168. doi: 10.1038/s41467-020-17965-0

Fig. 5. Survival and time to treatment failure in PBRM1 mutated MSKCC ccRCC patients by line of therapy.

Fig. 5

Overall survival (OS) and time-to-treatment failure (TTF) in MSK-IMPACT ccRCC (n = 173) stratified by a first line and b ≥second line of treatment (line of treatment not available in 12/185 patients).